| abstract |
It provides a method for producing a modified T cell comprising the step of introducing a first nucleic acid encoding the Nef protein into a precursor T cell, a modified T cell obtained by the method, and a pharmaceutical composition comprising the modified T cell, , When expressed, the Nef protein results in down-regulation of the endogenous T cell receptor (TCR) in the modified T cells, and the modified T cells also result in functional exogenous receptors such as engineered TCRs (eg chimeric TCR), T Cellular antigen coupler (TAC), TAC-like chimeric receptor or chimeric antigen receptor (CAR) is expressed. Also provided are non-naturally occurring Nef proteins comprising one or more mutations. |